<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="86837">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974687</url>
  </required_header>
  <id_info>
    <org_study_id>3682-001</org_study_id>
    <secondary_id>U1111-1149-5611</secondary_id>
    <secondary_id>IDX-04B-001</secondary_id>
    <secondary_id>2013-004043-23</secondary_id>
    <nct_id>NCT01974687</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Study of MK-3682 (IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)</brief_title>
  <official_title>A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-part study to evaluate the safety, tolerability, and pharmacokinetics (PK)
      of MK-3682 (IDX21437) in healthy participants and in participants infected with HCV genotype
      (GT)1-GT6. The effect of food on the PK of MK-3682 will be evaluated. The antiviral activity
      of MK-3682 will also be assessed in HCV-infected participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who experienced at least one adverse event (AE)</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced at least one serious adverse event (SAE)</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced dose-limiting toxicity (DLT)</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced at least one graded laboratory abnormality</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in HCV ribonucleic acid (RNA) levels</measure>
    <time_frame>Baseline and 28 days after last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration-time curve (AUC)</measure>
    <time_frame>Up to 120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum (peak) plasma drug concentration (Cmax)</measure>
    <time_frame>Up to 120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urine excretion</measure>
    <time_frame>Up to 120 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Healthy (Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will receive sequentially higher doses of MK-3682 (10 mg - 300 mg) capsules or matching placebo capsules once daily (QD) on Day 1 (Cohorts 1a-3a, 5a), Days 1 and 7 (Cohort 4a), or Day 1 - Day 7 (Cohort 6a). Dosing of next cohort will be based on review of available safety and PK data. Dosing will occur under fasted conditions with the exception of Cohort 4a, in which drug administration will occur under both fasted and fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV GT1 on Day 1 (Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1 participants with no prior direct-acting antiviral (DAA) exposure will receive a single dose of MK-3682 (10 mg - 300 mg) for 1 day across sequential dose cohorts. Dosing will commence following review of available safety and PK data from respective dose cohorts in Group A. All dosing will occur under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV GT1 for 7 days (Group C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1 participants will receive MK-3682 (50 mg - 400 mg in capsules or 300 mg or 450 mg in tablets) or matching placebo capsules QD for 7 days. Dosing will commence following review of available safety and PK data of Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV GT2 - HCV GT6 for 7 days (Group D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2 - GT6 participants will receive MK-3682 (50 mg - 300 mg) capsules QD for 7 days. Dosing will commence following review of available safety and PK data from Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV-GT1 for 1 or 7 days (Group E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1 participants with mildly impaired hepatic function will receive MK-3682 (150 mg - 450 mg) capsules QD for 1 or 7 days. Dosing of subsequent cohorts will be based on review of available safety and PK data. Fed vs. fasted dosing will be dependent on food effect results from Group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV GT1 Itraconazole + MK-3682 (Group F)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1 participants will receive itraconazole 200 mg twice daily (BID) on Day -5 and itraconazole 200 mg QD from Day -4 to Day 11. Participants will also be co-administered MK-3682 300 mg from Day 1 to Day 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3682</intervention_name>
    <description>MK-3682 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.</description>
    <arm_group_label>Healthy (Group A)</arm_group_label>
    <arm_group_label>HCV GT1 on Day 1 (Group B)</arm_group_label>
    <arm_group_label>HCV GT1 for 7 days (Group C)</arm_group_label>
    <arm_group_label>HCV GT2 - HCV GT6 for 7 days (Group D)</arm_group_label>
    <arm_group_label>HCV-GT1 for 1 or 7 days (Group E)</arm_group_label>
    <other_name>IDX21437</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to MK-3682 capsule administered by mouth.</description>
    <arm_group_label>Healthy (Group A)</arm_group_label>
    <arm_group_label>HCV GT1 for 7 days (Group C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.</description>
    <arm_group_label>HCV GT1 Itraconazole + MK-3682 (Group F)</arm_group_label>
    <other_name>SporanoxÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Participants:

          -  of childbearing potential must have agreed to use a double method of birth control
             (one of which must be a barrier) from Screening through at least 90 days after the
             last dose of the study drug

          -  must not have consumed grapefruit or grapefruit juice within 7 days of Day -1 and
             throughout the study

        HCV Participants:

          -  documented clinical history compatible with chronic hepatitis C.

          -  have not received direct-acting antiviral treatment for hepatitis C infection

          -  has HCV Genotype 1, 2, 3, 4, 5 or 6

        Exclusion Criteria:

        All Participants:

          -  pregnant or breastfeeding

          -  co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).

          -  decompensated liver disease

          -  other clinically significant medical conditions or laboratory abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 30, 2016</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C virus</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
